The CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY): design of a Phase III trial of oral cladribine in relapsing multiple sclerosis

被引：0
|
作者：
Giovannoni, G.
Comi, G.
Cook, S.
Beelke, M.
Rieckmann, P.
Sorensen, P. S.
Vermersch, P.
机构：
来源：
MULTIPLE SCLEROSIS | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S245 / S245
页数：1
相关论文
共 50 条
  • [21] Danish experience with cladribine tablets in the treatment of relapsing multiple sclerosis: a nationwide study
    Sorensen, P. S.
    Heick, A.
    Petersen, T.
    Joensen, H.
    Kopp, T. I.
    Sellebjerg, F.
    Magyari, M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 165 - 165
  • [22] Treating multiple sclerosis with generic cladribine
    Alvarez-Gonzalez, C.
    Allen-Philbey, K.
    Mathews, J.
    Espasandin, M.
    Turner, B. P.
    Gnanapavan, S.
    Marta, M.
    Giovannoni, G.
    Baker, D.
    Schmierer, K.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 604 - 605
  • [23] Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
    Gavin Giovannoni
    Joela Mathews
    Neurology and Therapy, 2022, 11 : 571 - 595
  • [24] NEDA-3 durability in CLARITY Extension in patients with relapsing multiple sclerosis receiving cladribine tablets
    Giovannoni, G.
    Keller, B.
    Jack, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 492 - 493
  • [25] Cladribine to Treat Relapsing Forms of Multiple Sclerosis
    Giovannoni, Gavin
    NEUROTHERAPEUTICS, 2017, 14 (04) : 874 - 887
  • [26] Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
    Giovannoni, Gavin
    Sorensen, Per Soelberg
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Comi, Giancarlo
    Dangond, Fernando
    Adeniji, Abidemi K.
    Vermersch, Patrick
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (12) : 1594 - 1604
  • [27] Cladribine to Treat Relapsing Forms of Multiple Sclerosis
    Gavin Giovannoni
    Neurotherapeutics, 2017, 14 : 874 - 887
  • [28] Cladribine tablets in high disease activity (HDA) subgroups from the CLARITY study of patients with relapsing multiple sclerosis (RMS)
    Giovannoni, G.
    Rammohan, K.
    Cook, S.
    Comi, G.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Dangond, F.
    Hicking, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 203 - 204
  • [29] Cladribine Tablets' Potential in Multiple Sclerosis Treatment
    Costello, Kathleen
    Sipe, Jack C.
    JOURNAL OF NEUROSCIENCE NURSING, 2008, 40 (05) : 275 - 280
  • [30] Consistent reductions in MRI activity with cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis in the CLARITY study
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Hamlett, A.
    Musch, B.
    Fevr, T.
    Viglietta, V.
    Greenberg, S. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 485 - 485
12345